Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
13345 results about "Immunology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunology is a branch of biology that covers the study of immune systems in all organisms. Immunology charts, measures, and contextualizes the physiological functioning of the immune system in states of both health and diseases; malfunctions of the immune system in immunological disorders (such as autoimmune diseases, hypersensitivities, immune deficiency, and transplant rejection); and the physical, chemical, and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo. Immunology has applications in numerous disciplines of medicine, particularly in the fields of organ transplantation, oncology, rheumatology, virology, bacteriology, parasitology, psychiatry, and dermatology.
Anti-PD-L1 antibodies, compositions and articles of manufacture
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:F HOFFMANN LA ROCHE & CO AG
Methods for selectively stimulating proliferation of T cells
InactiveUS6905681B1Increase the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Owner:GENETICS INST INC +2
Methods for selectively stimulating proliferation of T cells
InactiveUS6887466B2Expanding population of cellIncrease the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:GENETICS INST INC +2
Methods for selectively stimulating proliferation of T cells
InactiveUS7175843B2Increase the number ofBiocideCell receptors/surface-antigens/surface-determinantsAccessory moleculeExogenous growth
Owner:GENETICS INST LLC +2
Methods of treating HIV infected subjects
InactiveUS6905680B2Expanding population of cellIncrease the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:GENETICS INST INC +2
Methods for selectively stimulating proliferation of T cells
InactiveUS7144575B2Increase the number ofBiocidePeptide/protein ingredientsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY +2
Dual variable domain immunoglobulin and uses thereof
Owner:ABBVIE INC
Non-invasive prenatal diagnosis
InactiveUS6258540B1% accurate detection rateIncrease the amount of foetal nucleic acid materialMicrobiological testing/measurementRecombinant DNA-technologyPrenatal diagnosisBlood typing
The invention relates to a detection method performed on a maternal serum or plasma sample from a pregnant female, which method comprises detecting the presence of a nucleic acid of foetal origin in the sample. The invention enables non-invasive prenatal diagnosis including for example sex determination, blood typing and other genotyping, and detection of pre-eclampsia in the mother.
Owner:SEQUENOM INC
PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
ActiveUS20120039906A1Reduced activityStrong cytotoxicityAntibacterial agentsAnimal cellsPD-L1Antibody
Owner:INST JEAN PAOLI & IRENE CALMETTES +2
CD19-specific chimeric T cell receptor
InactiveUS7446179B2Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellular signallingTransmembrane domain
The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
Owner:CITY OF HOPE
Novel artificial antigen presenting cells and uses therefor
The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ActiveUS7217797B2Function increaseExtended half-lifeAnimal cellsSugar derivativesAntiendomysial antibodiesBiochemistry
Owner:ABBOTT BIOTHERAPEUTICS CORP
Antibody formulations
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
Owner:GENENTECH INC
Multispecific epitope binding proteins and uses thereof
InactiveUS20090155275A1Stimulate immune responseEnhanced interactionAntipyreticAnalgesicsEpitopeDisease
The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
Owner:MEDIMMUNE LLC
Fc-erythropoietin fusion protein with improved pharmacokinetics
InactiveUS20050192211A1Improve pharmacokineticsSimplify erythropoietin therapyPeptide/protein ingredientsAntibody mimetics/scaffoldsErythropoietinNucleic acid
The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.
Owner:MERCK PATENT GMBH
Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
ActiveUS20150079109A1Improve the level ofHigh expressionNervous disorderAntiviralsAntiendomysial antibodiesInfectious Disorder
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Owner:BEIGENE SWITZERLAND GMBH
Bivalent, bispecific antibodies
InactiveUS20090162359A1Increase productionImprove purification effectAnimal cellsHybrid immunoglobulinsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Antibodies against insulin-like growth factor 1 receptor and uses thereof
ActiveUS20050008642A1Slow tumor growthExtension of timeImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsBiologyAntibody
Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Recombinant anti-CD30 antibodies and uses thereof
The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
Owner:SEAGEN INC
Anti-IGF-I receptor antibody
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Stabilized single domain antibodies
InactiveUS20070178082A1Extended half-lifeAntibacterial agentsAntipyreticSingle-domain antibodySerum protein
The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and / or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
Owner:ABLYNX NV
Substance specific to human PD-1
The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and / or prevention of diseases caused by immunopathy.
Owner:HONJO TASUKU +1
T cell receptor-deficient t cell compositions
The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Bivalent, bispecific antibodies
InactiveUS20090175851A1Increase productionImprove purification effectAntibacterial agentsAntibody mimetics/scaffoldsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE INC
Fc variants with altered binding to FcRn
The present application relates to optimized IgG immunoglobulin engineering methods for their generation, and their application, particularly for therapeutic purposes.
Owner:XENCOR
Fc variants with altered binding to FcRn
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Owner:XENCOR INC
Methods and compositions for the treatment of persistent infections
ActiveUS20070122378A1Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsMicrobiologyPathology
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:DANA FARBER CANCER INST INC +3
Anti-VEGF antibodies
ActiveUS20070020267A1Inhibit bindingSenses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com